Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
View Patent ↗Novel salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
1. A crystalline form of atorvastatin sodium, wherein said x-ray powder diffraction pattern contains the following 2θ peaks measured using CuK α radiation: 3.4, 4.9, 7.6, 8.0 and 18.9.
2. A crystalline form of atorvastatin sodium wherein said x-ray powder diffraction pattern contains the following 2θ peaks measured using CuK α radiation: 3.4, 4.9, 7.6, 9.9 and 18.9.
3. A crystalline form of atorvastatin sodium wherein said x-ray powder diffraction pattern contains the following 2θ peaks measured using CuK α radiation: 3.4, 4.9, 7.6, 8.0, 9.9 and 18.9.
4. A crystalline form of atorvastatin sodium wherein said x-ray powder diffraction pattern contains the following 2θ peaks measured using CuK α radiation: 3.4, 4.9, 7.6, 18.9 and 19.7.
5. A crystalline form of atorvastatin sodium wherein said x-ray powder diffraction pattern contains the following 2θ peaks measured using Cuk α radiation: 3.4, 4.9, 7.6, 8.0, 18.9 and 19.7.
6. A crystalline form of atorvastatin sodium wherein said x-ray powder diffraction pattern contains the following 2θ peaks measured using CuK α radiation: 3.4, 4.9, 7.6, 8.0, 9.9, 18.9 and 19.7.
7. A crystalline form of atorvastatin sodium wherein said x-ray powder diffraction pattern contains the following 2θ peaks measured using CuK α radiation: 3.4, 4.1, 4.9, 5.6, 6.8, 7.6, 8.5, 9.9, 10.4, 12.8, 18.9, 19.7, 21.2, 22.1, 22.9, 23.3, 24.0 and 25.2.